Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Nivolumab Plus Radiation for Unresectable Head and Neck Mucosal Melanoma
KCT0004049Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in head and neck mucosal melanoma (HNMM), sponsored by Samsung Medical Center. Planned start Jul 2019; status: withdrawn.
02
Drugs
03
Conditions
head and neck mucosal melanoma (HNMM)
Beyond the preview
Go deeper on KCT0004049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004049.